What is Sense Neuro Diagnostics?
Sense Neuro Diagnostics operates at the intersection of advanced medical engineering and neurology, focusing on the critical need for rapid detection and continuous monitoring of brain injuries. The company is currently developing a suite of non-invasive technologies designed to identify stroke subtypes—including large vessel occlusion and intracerebral hemorrhage—with unprecedented speed and accuracy. By enabling real-time monitoring, the firm aims to transform the standard of care for stroke and traumatic brain injury patients, effectively reducing the time-to-treatment window which is vital for improving patient outcomes. Their market position is bolstered by ongoing pivotal trials and successful pilot studies, validating their approach to solving complex diagnostic challenges in emergency medicine.
How much funding has Sense Neuro Diagnostics raised?
Sense Neuro Diagnostics has raised a total of $1.6M across 3 funding rounds:
Private Equity
$250K
Private Equity
$1.3M
Debt
$76K
Private Equity (2017): $250K with participation from Accelerant
Private Equity (2017): $1.3M led by QCA Ventures
Debt (2021): $76K supported by PPP
Key Investors in Sense Neuro Diagnostics
Accelerant
Accelerant Dayton is a digital agency specializing in SEO consultancy and site optimization, providing strategic support to enhance the online visibility of high-growth enterprises.
QCA Ventures
QCA Ventures is an investor network dedicated to supporting early-stage companies through mentorship, deal sourcing, and strategic guidance for disruptive startups.
PPP
Public-Private Partnership
What's next for Sense Neuro Diagnostics?
With the recent influx of capital, Sense Neuro Diagnostics is well-positioned to accelerate its clinical development roadmap and scale its operational capabilities. The focus will likely shift toward the commercialization of its triage technology and the completion of its ongoing pivotal trials for intracranial hemorrhage monitoring. As the company moves into this next phase of maturity, the strategic deployment of these funds will be critical in navigating regulatory pathways and expanding its footprint within the global neuro-diagnostics market. Investors are closely watching the firm's ability to translate its technological innovations into clinical practice, which remains the primary driver for long-term value creation in the medical device sector.
See full Sense Neuro Diagnostics company page
